Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Sekisui XenoTech Hiring and Growing to Meet Customer Demand

Sekisui XenoTech
Posted on: 03 Jan 18
Sekisui XenoTech Hiring and Growing to Meet Customer Demand

Global Contract Research Organization Experiencing Growth Across All Departments

Kansas City, KS (January 3, 2018) – For over 20 years, Sekisui XenoTech has been known for its dedication to sound science, expert guidance and support in helping customers obtain data that meets or exceeds regulatory agency expectations when developing new therapeutics.
The company hired a record number of new staff over the past year in order to meet current demand for its products and services, which are utilized to optimize the discovery, development, and approval of new drugs and other compounds. Several previous Sekisui XenoTech employees also returned to the company. The new staff span Sekisui XenoTech’s contract research, quality assurance, business, IT, and other departments.
“Our hiring efforts are a reflection of our commitment to maintaining strict quality standards while meeting client needs and timelines,” explained Toshinari Ohara, PhD, CEO of Sekisui XenoTech. He added, “2017 ties 2011 for our second-highest number of new hires in a single year.”
One of the new additions was industry veteran Darren Warren, PhD, who became the company’s new COO in October. Upon joining Sekisui XenoTech, Dr. Warren noted, “I am excited to become a member of an organization with the distinguished performance history, leadership team strength, depth of scientific expertise, and position of market leadership that Sekisui XenoTech enjoys, and that holds an optimistic outlook towards future growth while maintaining commitment to excellence in providing a positive customer experience as well as outstanding contract services and products.”
In addition to growth, the company has made other internal changes. Dr. Ohara commented, “While hiring talent from outside the organization has many positive effects, such as introducing new ideas and expertise, we have also been focused on ongoing training and career advancement for our existent staff.” Sekisui XenoTech awarded numerous promotions to its staff this year, which prominently included elevating Joanna Barbara, PhD, to the position of Vice President of Scientific Operations and Brian Ogilvie, PhD, to the position of Vice President of Scientific Consulting. Joanna and Brian share a combined 30 years of experience with the company.
Sekisui XenoTech’s current open positions, management bios and more are available at
About Sekisui XenoTech
Sekisui XenoTech, LLC is a global Contract Research Organization utilized by 98% of top pharma companies and numerous other organizations. For over 20 years, the company has offered proven expertise from discovery through clinical support, providing an ever-evolving selection of cell and tissue-based products, screening, radiolabeling, API manufacturing, in vitro ADMET and pharmacology, in vivo ADMET and QWBA, metabolite ID and production, bioanalytical services and consulting. Sekisui XenoTech's product selection includes a wide range of high-quality unique and standard reagents, including subcellular fractions, hepatocytes, media, tissue samples, cell lines, recombinant enzymes, substrates, metabolites and more. The company also regularly prepares and delivers custom-designed products and services in response to client requests. For additional information, please refer to the company's website at

For more information:

Editor's Details

Michael Millhollen
Sekisui XenoTech

Last updated on: 03/01/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.